Correlation between the degree of CP21 E-cadherin expression and the grade of tumor differentiation, as well as the histological type according to the Lauren and the WHO ?classifications. Patients with E-cadherin-positive tumors have significantly KDM5A-IN-1 better 3- and 5-year survival rates than patients with E-cadherin-negative tumors [28]. Hereditary diffuse gastric cancer (HDGC) is a rare autosomal dominant syndrome that is largely attributable to germline mutations and deletions in the CDH1 gene associated with an early onset, histologically diffuse, signetring cell type gastric cancer [29,30]. Lim JY et al reported that PKM2 expression was strongly correlated with gastric cancer differentiation. Differentiated types of cancers express more PKM2 protein than the undifferentiated types; in contrast, higher PKM2 expression is correlated with shorter overall survival independent of stage in signet-ring cell cancers. PKM2 expression might be an adverse prognostic factor for signet-ring cell carcinomas, which lack E-cadherin [7]. These results are in accordance with our research in gastric cancer cells. The BGC-823, SGC-7901 and AGS cell lines are differently differentiated types. E-cadherin expression exists in the SGC-7901 and BGC-823 cell lines; in contrast, the AGS cells were derived from malignant gastric adenocarcinoma tissue and lack E-cadherin-mediated cell adhesion [31]. We observed that the knockdown of PKM2 promoted the migration and invasion of the SGC-7901 and BGC-823 cell lines but suppressed these properties in the AGS cell line. Another group has reported that pyruvate kinase type M2 is upregulated in colorectal cancer, and the knockdown of PKM2 suppressed the proliferation and migration of colon cancer RKO cells [32]. We know that RKO cells lack the expression of E-cadherin [33]. Immunohistochemical (IHC) analysis demonstrates that the levels of E-cadherin expression, ERK1/2 phosphorylation, and cytoplasmic PKM2 expression were correlated with each other. We found a high level of ERK1/ 2 phosphorylation in the nucleus of cancer cells without Ecadherin expression but with a high level of PKM2 expression. We hypothesize that PKM2 attenuates cell motility and invasion when E-cadherin is present. This novel function of PKM2 may play a role in the reversible inhibition of cell 23148522 motility and invasion in the early stages of gastric cancer when cells are positive for Ecadherin expression. During the progression of the tumor, a lack of or very low expression of E-cadherin induces an aggressive function of PKM2 in the tumor. The biological role of PKM2 in the development of these tumors must be further elucidated.Supporting InformationFigure S1 The expression of the EGFR protein in the gastric cancer cell lines BGC823, SGC7901 and AGS was evaluated using Western blot analysis. AGS cells showed a higher level of EGFR expression than the other two cell lines. There is no significant difference between BGC823 and SGC7901 cells (Figure S1A). BGC-pu6 cells and BGC-sipk cells were treated with different doses of EGF. After 40 minutes we detected the level of phosphorylation for EGFR. We found the highest level of phosphorylation in the dose of 100ng/ml (Figure S1B). Therefore we chose the dose of 100ng/ml as the most suitable candidate. The transwell experiment also showed the stronger ability to penetrate the martrigel in BGC823 cells (Figure S1C). (TIF)Author ContributionsConceived and designed the experiments: BG JLR LGC. Performed the experiments.Correlation between the degree of E-cadherin expression and the grade of tumor differentiation, as well as the histological type according to the Lauren and the WHO ?classifications. Patients with E-cadherin-positive tumors have significantly better 3- and 5-year survival rates than patients with E-cadherin-negative tumors [28]. Hereditary diffuse gastric cancer (HDGC) is a rare autosomal dominant syndrome that is largely attributable to germline mutations and deletions in the CDH1 gene associated with an early onset, histologically diffuse, signetring cell type gastric cancer [29,30]. Lim JY et al reported that PKM2 expression was strongly correlated with gastric cancer differentiation. Differentiated types of cancers express more PKM2 protein than the undifferentiated types; in contrast, higher PKM2 expression is correlated with shorter overall survival independent of stage in signet-ring cell cancers. PKM2 expression might be an adverse prognostic factor for signet-ring cell carcinomas, which lack E-cadherin [7]. These results are in accordance with our research in gastric cancer cells. The BGC-823, SGC-7901 and AGS cell lines are differently differentiated types. E-cadherin expression exists in the SGC-7901 and BGC-823 cell lines; in contrast, the AGS cells were derived from malignant gastric adenocarcinoma tissue and lack E-cadherin-mediated cell adhesion [31]. We observed that the knockdown of PKM2 promoted the migration and invasion of the SGC-7901 and BGC-823 cell lines but suppressed these properties in the AGS cell line. Another group has reported that pyruvate kinase type M2 is upregulated in colorectal cancer, and the knockdown of PKM2 suppressed the proliferation and migration of colon cancer RKO cells [32]. We know that RKO cells lack the expression of E-cadherin [33]. Immunohistochemical (IHC) analysis demonstrates that the levels of E-cadherin expression, ERK1/2 phosphorylation, and cytoplasmic PKM2 expression were correlated with each other. We found a high level of ERK1/ 2 phosphorylation in the nucleus of cancer cells without Ecadherin expression but with a high level of PKM2 expression. We hypothesize that PKM2 attenuates cell motility and invasion when E-cadherin is present. This novel function of PKM2 may play a role in the reversible inhibition of cell 23148522 motility and invasion in the early stages of gastric cancer when cells are positive for Ecadherin expression. During the progression of the tumor, a lack of or very low expression of E-cadherin induces an aggressive function of PKM2 in the tumor. The biological role of PKM2 in the development of these tumors must be further elucidated.Supporting InformationFigure S1 The expression of the EGFR protein in the gastric cancer cell lines BGC823, SGC7901 and AGS was evaluated using Western blot analysis. AGS cells showed a higher level of EGFR expression than the other two cell lines. There is no significant difference between BGC823 and SGC7901 cells (Figure S1A). BGC-pu6 cells and BGC-sipk cells were treated with different doses of EGF. After 40 minutes we detected the level of phosphorylation for EGFR. We found the highest level of phosphorylation in the dose of 100ng/ml (Figure S1B). Therefore we chose the dose of 100ng/ml as the most suitable candidate. The transwell experiment also showed the stronger ability to penetrate the martrigel in BGC823 cells (Figure S1C). (TIF)Author ContributionsConceived and designed the experiments: BG JLR LGC. Performed the experiments.
